{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:25:25Z","timestamp":1793946325270,"version":"4.8.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["BIP-00058-24"],"award-info":[{"award-number":["BIP-00058-24"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["APQ-00251-21"],"award-info":[{"award-number":["APQ-00251-21"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["APQ-00399-20"],"award-info":[{"award-number":["APQ-00399-20"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jim.2026.114059","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T23:05:31Z","timestamp":1778367931000},"page":"114059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Integrated workflow for production and in vitro characterization of equine anti-SARS-CoV-2 hyperimmune serum with epitope mapping"],"prefix":"10.1016","volume":"548","author":[{"given":"Karla","family":"de Santana Evangelista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson","family":"de Castro Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"de Souza Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Ardisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline Andrade","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia Ferreira","family":"Boasquivis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrian Morato","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara","family":"de Oliveira Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Job Alves","family":"de Souza Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia Helena","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladstony","family":"de Oliveira Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Ch\u00e1vez","family":"Ol\u00f3rtegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisson Bruno","family":"Luzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio","family":"Caldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2026.114059_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.871874","article-title":"Equine anti-SARS-CoV-2 serum (ECIG) binds to mutated RBDs and N proteins of variants of concern and inhibits the binding of RBDs to ACE-2 receptor","volume":"13","author":"Andrade","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jim.2026.114059_bb0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.nbt.2011.03.018","article-title":"Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology","volume":"28","author":"Berry","year":"2011","journal-title":"New Biotechnol."},{"key":"10.1016\/j.jim.2026.114059_bb0015","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-07793-1","article-title":"Anti-SARS-CoV-2 equine F (Ab\u2019)2 immunoglobulin as a possible therapy for COVID-19","volume":"12","author":"Botosso","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jim.2026.114059_bb0020","doi-asserted-by":"crossref","DOI":"10.1590\/1678-4324-2025230848","article-title":"Equine hyperimmune serum against the inactivated SARS-CoV-2 has antibodies neutralizing titers","volume":"68","author":"Conrad","year":"2025","journal-title":"Braz. Arch. Biol. Technol."},{"key":"10.1016\/j.jim.2026.114059_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103315","article-title":"Polyclonal F(ab\u2019)2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency","volume":"24","author":"Cunha","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.jim.2026.114059_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107220","article-title":"COVID-19 and hyperimmune sera: a feasible plan B to fight against coronavirus","volume":"90","author":"da Costa","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jim.2026.114059_bb0035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/v17020165","article-title":"Immunogenic potential of selected peptides from SARS-CoV-2 proteins and their ability to block S1\/ACE-2 binding","volume":"17","author":"da Silva Lima","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.jim.2026.114059_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2021.101588","article-title":"New Brazilian variant of the SARS-CoV-2 (P1\/Gamma) of COVID-19 in Alagoas state","volume":"25","author":"da Silva","year":"2021","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.jim.2026.114059_bb0045","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.molimm.2022.05.012","article-title":"Influence of SARS-CoV-2 inactivation by different chemical reagents on the humoral response evaluated in a murine model","volume":"147","author":"de Castro Barbosa","year":"2022","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jim.2026.114059_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jviromet.2023.114742","article-title":"Potential use of high-resolution melting analyses for SARS-CoV-2 genomic surveillance","volume":"317","author":"de Souza Andrade","year":"2023","journal-title":"J. Virol. Methods"},{"issue":"11","key":"10.1016\/j.jim.2026.114059_bb0055","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/s41587-020-0732-8","article-title":"COVID-19 antibodies on trial","volume":"38","author":"DeFrancesco","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jim.2026.114059_bb0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-1759(02)00137-0","article-title":"The SPOT-synthesis technique: synthetic peptide arrays on membrane supports - principles and applications","volume":"267","author":"Frank","year":"2002","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2026.114059_bb0065","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jim.2026.114059_bb0070","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1590\/S0104-79301998000100007","article-title":"Production of an effective anti-bothrops-tetanus mixed hyperimmune serum of equine origin","volume":"4","author":"Guidolin","year":"1998","journal-title":"J. Venom. Anim. Toxins"},{"key":"10.1016\/j.jim.2026.114059_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.108981","article-title":"Equine immunoglobulin fragment F(ab\u2019)2 displays high neutralizing capability against multiple SARS-CoV-2 variants","volume":"237","author":"Gupta","year":"2022","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jim.2026.114059_bb0080","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1128\/JVI.79.6.3289-3296.2005","article-title":"Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents","volume":"79","author":"Keng","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.jim.2026.114059_bb0085","series-title":"Potency, and Safety, Current Laboratory Techniques in Rabies Diagnosis, Research and Prevention","first-page":"293","article-title":"Production of equine rabies immune globulin of high purity","volume":"2","author":"Khomvilai","year":"2015"},{"key":"10.1016\/j.jim.2026.114059_bb0090","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-1759(02)00140-0","article-title":"Application of the spot method to the identification of peptides and amino acids from the antibody paratope that contribute to antigen binding","volume":"267","author":"Laune","year":"2002","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2026.114059_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-89242-z","article-title":"Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19","volume":"11","author":"Le\u00f3n","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jim.2026.114059_bb0100","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1745-7254.2005.00210.x","article-title":"Preparation and development of equine hyperimmune globulin F(ab\u2019)2 against severe acute respiratory syndrome coronavirus","volume":"26","author":"Lu","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jim.2026.114059_bb0105","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.3201\/eid2608.201246","article-title":"US CDC real-time reverse transcription PCR panel for detection of severe acute respiratory syndrome coronavirus 2","volume":"26","author":"Lu","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.jim.2026.114059_bb0110","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent Covid-19","volume":"385","author":"O\u2019Brien","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2026.114059_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104868","article-title":"Immunoglobulin fragment F(ab\u2019)2 against RBD potently neutralizes SARS-CoV-2 in vitro","volume":"182","author":"Pan","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jim.2026.114059_bb0120","article-title":"An evaluation of the safety and potency of equine rabies immunoglobulin through measurement of suppression on vaccine-induced antibody production among healthy volunteers","volume":"52","author":"Salva","year":"2014","journal-title":"Philipp. J. Intern. Med."},{"key":"10.1016\/j.jim.2026.114059_bb0125","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.vaccine.2005.08.055","article-title":"A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses","volume":"24","author":"Spruth","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2026.114059_bb0130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4269\/ajtmh.1990.42.175","article-title":"Equine rabies immune globulin: a product with an undeserved poor reputation","volume":"42","author":"Wilde","year":"1990","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.jim.2026.114059_bb0135","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.intimp.2007.09.011","article-title":"Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab\u2019)2 in macaque","volume":"7","author":"Xu","year":"2007","journal-title":"Int. Immunopharmacol."},{"issue":"Suppl. 3","key":"10.1016\/j.jim.2026.114059_bb0140","first-page":"1","article-title":"Development of a hyperimmune equine serum therapy for COVID-19 in Argentina","volume":"80","author":"Zylberman","year":"2020","journal-title":"Medicina (B Aires)"}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175926000359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175926000359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:28:57Z","timestamp":1793942937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175926000359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":28,"alternative-id":["S0022175926000359"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2026.114059","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated workflow for production and in vitro characterization of equine anti-SARS-CoV-2 hyperimmune serum with epitope mapping","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2026.114059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114059"}}